All In Biotech

Drug Trial Radar · NCT02312258

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 706 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

706

Actual

Start

Apr 9, 2015

Primary completion

Aug 12, 2019

Study completion Aug 26, 2022

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to initial therapy and who have not undergone SCT.

Conditions

  • Multiple Myeloma

Interventions

  • PlaceboDrug

    Ixazomib placebo-matching capsules.

  • IxazomibDrug

    Ixazomib capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From randomization until PD or death (up to 52 months)

Locations

275 sites in 35 countries. Site status is shown where the registry gives one.

  • Robert A Moss MD FACP Inc

    Fountain Valley, California

  • UCLA Medical Hematology and Oncology

    Los Angeles, California

  • North County Oncology Medical Clinic Inc

    Oceanside, California

  • Ventura County Hematology Oncology Specialists

    Oxnard, California

  • Emad Ibrahim, MD, Inc

    Redlands, California

  • Global Cancer Research Institute (GCRI), Inc.

    San Jose, California

  • Central Coast Medical Oncology Corporation

    Santa Maria, California

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • John H. Stroger Jr. Hospital of Cook County

    Chicago, Illinois

  • Siouxland Hematology - Oncology Associates LLP

    Sioux City, Iowa

  • Appalachian Regional Healthcare

    Hazard, Kentucky

  • New England Cancer Specialists

    Scarborough, Maine

  • Saint Agnes Hospital - Baltimore - Hunt - PPDS

    Baltimore, Maryland

  • University Hospital of Wales -

    Bethesda, Maryland

  • Tufts Medical Center - PPDS

    Boston, Massachusetts

  • Herbert-Herman Cancer Center

    Lansing, Michigan

  • Clinical Research Alliance Inc

    New York, New York

  • New York Presbyterian Hospital - Weill-Cornell

    New York, New York

  • Cancer Care of WNC PA

    Asheville, North Carolina

  • UPMC Cancer Pavillion

    Pittsburgh, Pennsylvania

  • HOPE Cancer Center of East Texas

    Tyler, Texas

  • Swedish Cancer Institute

    Seattle, Washington

  • W VA University Mary Babb Randolph Cancer Center

    Morgantown, West Virginia

  • Sanatorio Allende S.A.

    Córdoba, Argentina

  • Hospital Iturraspe

    Santa Fe, Argentina

  • Hospital Universitario Austral

    Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina

  • Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)

    Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina

  • St Vincents Hospital Melbourne - PPDS

    Fitzroy, Victoria, Australia

  • Frankston Hospital

    Frankston, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Paracelsus Medizinische Privatuniversitat

    Salzburg, Austria

  • Medizinische Universitat Wien (Medical University of Vienna)

    Vienna, Austria

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Austria

  • Universitatsklinikum Innsbruck

    Innsbruck, Tyrol, Austria

  • Universitair Ziekenhuis Brussel - PIN

    Brussels, Brussels Capital, Belgium

  • UZ Brussel

    Brussels, Brussels Capital, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Brussels Capital, Belgium

  • HEMORIO - Unidade de Pesquisa Clinica

    Rio de Janeiro, Brazil

  • Instituto Nacional de Cancer

    Rio de Janeiro, Brazil

Showing 40 of 275 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.